Skip to main content
THE POWER OF VIBRANCE
Notices | Media Release | Trading Holidays | BSEPlus | BSE SME | Payments to BSE | Contact us | FeedBack
THE POWER OF VIBRANCE
BSE SENSEX
82,259.24
-375.24 -0.45%
17 Jul 25 | 16:00 | Close

Get Quote

    Kilitch Drugs India Ltd

    16
    (KILITCH | 524500 | INE729D01010)
    454.00 -9.25 (-2.00%) Periodic Call Auction
    Average daily number of unique Clients/PAN traded in the scrip in previous 30 days is less than 100 | View More  
    17 Jul 25 | 16:00 | All Prices in   

    ESM :Stage 2

    Previous Close 463.25
    Open 454.00
    High 454.00
    Low 454.00
    VWAP 454.00
    52 Wk High 490.00
    52 Wk Low 265.60
    Upper Price Band 463.05
    Lower Price Band 444.95
    Price Band 2%
    TTQ 39
    Turnover (Lakh) 0.18
    2W Avg Qty` 3478
    Mcap Full (Cr.) 793.63
    Mcap FF (Cr.) 232.69
    EPS (TTM) 19.37
    CEPS (TTM) 20.45
    PE/PB 23.44 / 3.08
    ROE 13.15
    Face Value 10.00
    Category Listed
    Group / Settlement Type T /T+1
    Index -
    Basic Industry Pharmaceuticals

    Related Party Transactions : Quarter ending :Sep 2024

    Archives
    ₹ in Millions

    General information about company
    Name of The CompanyKILITCH DRUGS (INDIA) LIMITED
    BSE Scrip Code524500
    Date of Start of Financial Year01/04/2024
    Date of End of Financial Year31/03/2025
    Reporting PeriodFirst half yearly
    Date of Start of Reporting Period01/04/2024
    Date of End of Reporting Period30/09/2024
    Level of rounding to be used in disclosing related party transactionsMILLIONS
    Whether the company has any related party?Yes
    Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?Yes

    (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
    (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank’s staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
    (III) Whether the company is a ‘high value debt listed entity’ according to regulation 15 (1A)? No
    (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
    (b) If answer to above question is No, please explain the reason for not complying. Textual Information(1)

    Text Block

    Textual Information(1)

    Related party transactions
    Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
    Sr No. Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
    Name Name Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
    1 Kilitch Drugs India Ltd Mukund Mehta Managing Director Remuneration NA 2.75 0 0
    2 Kilitch Drugs India Ltd Bhavin Mehta Wholetime Director Remuneration NA 3.85 0 0
    3 Kilitch Drugs India Ltd Mira Mehta Managing Director Remuneration NA 1.1 0 0
    4 Kilitch Drugs India Ltd Sunil Jain Chief Financial Officer Remuneration NA 0.931 0 0
    5 Kilitch Drugs India Ltd Pushpa Nyoupane Company Secretary Remuneration NA 0.339 0 0
    6 Kilitch Drugs India Ltd Hemang Jagdish Engineer Non Executive and Independent Director Any other transaction Sitting Fees NA 0.015 0 0
    7 Kilitch Drugs India Ltd V. S. Rajan Non Executive and Independent Director Any other transaction Sitting Fees NA 0.003 0 0
    8 Kilitch Drugs India Ltd V. K. Murti Non Executive and Independent Director Any other transaction Sitting Fees NA 0.025 0 0
    9 Kilitch Drugs India Ltd NBZ Healthcare LLP Few Directors are Partner Purchase of goods or services 25 NA 0 9.715 9.715
    10 Kilitch Drugs India Ltd NBZ Healthcare LLP Few Directors are Partner Advance 120 NA 29.506 42.41 71.916 Advance 0 on demand Unsecured Business Activity
    11 Kilitch Drugs India Ltd Kilitch Company Pharma Limited Few Directors are Director Advance 5 NA 0.064 0.098 0.161 Advance 0 on demand Unsecured Business Activity
    12 Kilitch Drugs India Ltd Kilitch Estro Biotech PLC Foreing Subsidiary Sale of goods or services 25 NA 0.021 0 0.021
    13 Kilitch Drugs India Ltd Kilitch Estro Biotech PLC Foreing Subsidiary Advance 25 NA 0 426.377 426.377 Loan 4 on demand Unsecured Business Activity
    14 Kilitch Drugs India Ltd Monarchy Healthserve Pvt Ltd Wholly Owned Subsidiary Advance 10 NA 0.17 3.755 3.926 Advance 0 on demand Unsecured Business Activity
    Total value of transaction during the reporting period 38.774


    Site optimized for IE9 & above. | Disclaimer | Website Policies | Privacy Policy | Sitemap Copyright © BSE Ltd. All Rights Reserved.
    18 Jul 25 | 04:56 (IST)
    (94)